Author/Authors :
Javidi, Fatemeh School of Medicine - Arak University of Medical Sciences, Arak, Iran , Yousefichaijan, Parsa Amir Kabir Hospital - Department of Pediatric Nephrology - Arak University of Medical Sciences, Arak, Iran , Dorreh, Fatemeh Department of Pediatric - Arak University of Medical Sciences, Arak, Iran , Arjmand, Ali Department of Pediatric - Arak University of Medical Sciences, Arak, Iran , Rezagholizamenjany, Masoud School of Medicine - Arak University of Medical Sciences, Arak, Iran
Abstract :
Background: Montelukast, as a non-steroidal anti-inflammatory drug, could reduce inflammation in nephrotic syndrome (NS).
This study aimed to evaluate the therapeutic effect of montelukast as adjunctive therapy in pediatric NS.
Methods: This clinical trial study was conducted on patients with NS. The patients were assigned into two equal groups (N = 25 in each) of intervention (steroid + montelukast) and control and treated for one month. One month later, in the follow-up stage, their
proteinuria was measured. The results before and after treatment were statistically analyzed by SPSS software version 21, and the
final report of the project was presented.
Results: The age of participants in the intervention and control groups was 7.264.23 and 6.793.91 years, respectively (P = 0.68),
andthere were 10 female participants in both groups (P=1.0). Albuminlevels in 96% of the control groupand76% of the intervention
group were 1.5 - 2.5 g/dL (P = 0.037). Also, 48% of participants in the control group were corticosteroid dependent, and 60% of
participants in the intervention group responded to corticosteroids (P = 0.194). The severity of nephrotic syndrome was moderate
in 60% of participants in the control group and mild in 60% of participants in the intervention group (P = 0.138).
Conclusions: The results of this study showed that recovery rate was higher in the intervention group, but the difference was not statistically significant.
